SVARNA – VANGA – A SHORT DURATION TOXICITY STUDY by Sharma, et al.
Pages 86 - 90 
 
 
 
 
Ancient Science of Life,                                                                       Vol.V,  No.. 2  October 1985, Pages 86 - 90 
 
 
SVARNA – VANGA – A SHORT DURATION TOXICITY STUDY 
 
SHARMA *, GYANESHWAR*, JOSHI. D., ARYYA. N. C. ** and PANDEY. V. B. *** 
 
Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221 005, India 
* Dept. of Rasa Shastra 
** Dept. of Pathology 
*** Dept. of Medicinal Chemistry 
 
Received: February 04, 1985                                                                  Accepted: May 30, 1985 
ABSTRACT: Swarna – Vanga, an Ayurvedic preparation, is used in the treatment mainly of 
Pramehas (genitor urinary and metabolic disorders), Sveta Pradara (Leucorrhoea), Kasa – 
Swasa (Respiratory disorders), etc.  The drug contains tin and sulphur as major components 
along with traces of mercury, iron and aluminum.  According to modern point of view certain 
metals have been claimed toxic to both human and animal.  Since Svarna – Vanga contains these 
metals, it is essential to screen out its toxic effect, if any, although it is claimed in Ayurveda that 
when a metal is processed as prescribed, it become non – toxic or the least toxic.  Considering 
the above facts, an animal experiment was carried out for short duration (14 days) to screen the 
toxic effects of Svarna – Vanga (SV) in increasing doses of the drug starting from the maximum 
therapeutic dose (12.5 mg / 100 gm b.wt / day).  The drug was found to have no toxic effects in 
tissues of the animal at doses of 12.5 mg and 25 mg / 100 gm b.wt. / day.  Fine fatty 
vacuolization in liver and focal superficial mucosal degeneration and necrosis of small intestine 
confined to one animal each at dose of 50 mg / 100gm b.wt. and 100 mg/ 100 gm. b.wt. / day 
were observed.  Our study indicates that the drug has no toxic effect on tissues at therapeutic 
dose. 
 
INTRODUCTION 
 
The drug Svarna –  Vanga, an Ayurvedic 
preparation has been in use as a medicine 
since 14
th century A. D. 
1 Svarna – Vanga 
(SV) is a metallic preparation which 
contains mainly Tin and Sulphur along with 
traces of Mercury, Iron and Aluminium
2.  
Metals particularly the heavy metals are 
known to have toxic effects and therefore 
having limited therapeutic uses.  Salts of 
heavy metals (except Hg) are absorbed 
slowly from G.I.T., but the presence of 
gastrointestinal lesions and particularly 
when the salt itself induces irritation and 
congestion, relatively more metal is 
absorbed than in normal epithelium.     
Slowly absorbed metals, if, excreted even 
more gradually may lead to tissue 
accumulation on repeated administration and 
thus to chronic toxicity
3.  Since SV contains 
Tin, Sulphur, mercury, iron and aluminum, 
evaluation of its toxic effects, if any, is 
essential for its safe use in medical practice.  
The present animal experimental study was 
carried out to screen the toxic effects of SV 
on various tissues of animals (albino rats) 
kept on increasing doses starting from Pages 86 - 90 
 
 
maximum therapeutic doses (12.5 mg / 100 
gm b.wt./day)
4  of Svarna –  Vanga for a 
duration of 14 days. 
 
  MATERIALS AND METHODS 
 
 
Svarna  –  Vanga was prepared as per 
Ayurvedic methods (Kupipaka method) 
using Tin (1 part), Mercury (1/2 part), 
Sulphur (1 part), Nausadara (1  part) and 
Kalmi  –  Shora (1/10 part).  The finished 
product (SV) contains Tin (53.25%), 
Mercury (0.81%), Sulphur (24.50%) and 
Iron, Aluminum in traces
5. 
 
The drug was administered in suspension 
form (gum acacia 20% suspension) at 
different doses to 4 groups (6 animals in 
each) of albino rats as follows: 
 
 
Group  Dose of drug  
(per 100 gm of body weight / day) 
Duration of drug 
administration 
I 
 
II 
 
III 
 
IV 
 
Control 
12.5 mg 
 
25 mg 
 
50 mg 
 
100 mg 
 
Only 20% gum acacia suspension, 
1 ml / 100 gm 
14 days 
 
14 days 
 
14 days 
 
14 days 
 
14 days 
 
 
Animals, during the period of experiment 
were closely observed for any behavioural 
change.  On 16
th  days all the animals 
including the control group were sacrificed 
by decapitation method, their visceras were 
dissected out  and fixed in 10% formalin.     
Sections (2 –  4) from the tissues were 
processed for histopathologic examination 
by using standard laboratory technique 
(Culling, 1963).  Haematoxylineosin stained 
sections and in some cases PAS and 
Reticulin preparations were  available for 
light microscopic study. 
 
Observation 
 
None of the animals showed any 
behavioural change during the course of the 
experiment.  Macroscopic examination of 
the viscera and organs revealed no 
significant pathologic change.  Microscopic 
findings  of tissues in different groups of 
animals are as follows- 
 
Animals treated with 12.5 mg and 25 mg / 
100 gm b.wt. / day of Svarna –  Vanga 
revealed no significant change in their 
organs and visceras.  In almost all animals, 
non – specific changes in the form of mild 
cloudy swelling of the kidney tubules,  and 
congestion of liver, spleen and lung were 
observed.  Brain, heart, pancreas, adrenals, 
skin, bone marrow, G.I.T and big vessels of 
heart were quite normal in appearance. 
 
Among the animals treated with 50 mg / 100 
gm of b.wt/ day of Svarna –  Vagna, no 
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observed in heart, brain, bone –  marrow, 
skin, pancreas, adrenals, and skeletal 
muscles.  Congestion of mild degrees in 
liver, lung and spleen was noted.  Liver 
tissue in one animal revealed congestion and 
dilatation of central vein and sinusoids along 
with fine fatty vacuoles in hepatocytes 
(Fig.1).  Except mild degrees of cloudy 
swelling in tubules, kidney tissue revealed 
no other significant change.  Extensive 
bronchial  lymphoid hyperplasia, mucosal 
atrophy and focal squamous metaplasia of 
bronchial mucosa (Fig. 2) were noted in one 
animal.  Small intestine in one animal 
revealed focal superficial mucosal 
degeneration and necrosis (Fig. 3). 
 
Animals kept on Svarna – Vanga at a dose 
of 100 mg/ 100 gm b.wt / day showed 
certain changes in liver and intestine.  Fine 
fatty vacuoles in hepatocytes in one animal 
and focal superficial mucosal degeneration 
and necrosis of small intestine in one animal 
were observed.  Mild congestion in lung, 
liver and spleen and cloudy swelling in 
kidney tubules were also observed.  Other 
organs and visceras of animals of this group 
like brain, heart, pancreas, bone – marrow 
and skeletal muscles were normal looking. 
 
DISCUSSION 
 
Certain salts of Tin (Stannous and Stannic 
chloride; dibutyl tin chloride; tine mallate; 
tin sulphate, orthophosphate, oxalate and 
tartrate; sodium pentfluoro – stannite etc.)
6 
at different doses have been found toxic to 
animals and human beings.  Evidences of 
irritative effect of soluble tin salts on gastric 
mucosa
7; homogenous cell cytoplasm, fatty 
changes and bile duct hyperplasia in liver
8; 
degeneration and necrosis of renal tissues
9 
are available.  But no salt of above studies 
resemble to our drug composition.  In a 
study de Groot et al (1973) found no 
pathologic changes in liver, kidney, heart 
and spleen of the animals following tin 
sulphide at dietary level up to 10 gm / kg for 
4 weeks.  Though Svarna – Vanga  contains 
tin, sulphur, mercury, iron and aluminum, it 
showed no toxic effects on various tissues of 
animals kept for 14 days up to dose of 25 
mg / 100 gm of b.wt / days of the drug 
which is much higher than the therapeutic 
dose.  Non – toxicity of Svarna – Vanga up 
to 25 mg dose may be due to different type 
of salt of tin present in the drug which is 
harmless to animal tissue or the method of 
Ayurvedic preparation of Svarna –  Vanga 
which renders.  Tin and other ingredients 
non – toxic. 
 
Pathologic changes in liver, bronchial 
mucosa and small intestine may be related to 
the toxic effects of the ingredients (Sn, Hg. 
S. etc) of Svarna – Vanga at much higher 
doses or due to some other aetiology which 
escaped even after study of multiple sections 
of the tissues.  In this regard further study on 
larger groups of animals, proper chemical 
analysis of the drug and changes that occur 
on chemical nature of metals following 
application of Ayurvedic method of 
preparation of metallic drug is of paramount 
importance for the safe use of the drug. 
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CONCLUSIONS 
 
From the observations of our experimental 
study conducted for a period of 14 days, it 
can be concluded that Svarna – Vanga has 
no toxic effect on various tissues of albino 
rats up to the dose of 25 mg / 100 gm b.wt. / 
day which is much higher than the 
maximum therapeutic dose (12.5 mg / 100 
mg b.wt. / day) employed in Ayurvedic 
practice.  Thus Svarna – Vanga appears to 
be non –  toxic at therapeutic dose.   
Pathologic changes observed in liver, 
bronchial mucosa and small intestine at 50 
mg and 100 mg / 100 gm b.wt. / day doses 
need further confirmation by detailed 
experimental study conducted on larger 
groups of animals. 
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Description of Photographs 
 
Fig. No.1   Photomicrograph showing fine fatty vacuoles in hepatocytes (H & E x 125). 
 
Fig. No.2  Photomicrograph showing squamous metaplasia of bronchial mucosa  
(H & E x 125). 
 
Fig. No. 3  Photomicrograph showing superficial mucosal degeneration and necrosis in small  
     intestine (H & E. x 125) 
 
 
 
 